tbuckley/cabot-search huggingface dataset:
INHIBITION OF LEUKOCYTE MIGRATION BY THE AGAROSE PLATE TECHNIQUE
Authors: EJVIND BUDTZ‐JØSRGENSEN
Journal: Allergy (1977)

Leukocyte migration inhibition by antigen from Candida albicans and Fusobacterium nucleatum was studied in man by means of the direct leukocyte migration agarose technique (LMAT). Antigens were prepared by prolonged ultrasonication and were added to the leukocyte cultures in the original as well as in the concentrated solutions. Significant inhibition of migration with a 10-fold concentrated solution of candida antigen was demonstrated in subjects showing apositive intracutaneous reaction to candida. With the fusobacterial antigen, inhibition of migration or stimulation of migration were demonstrated in subjects with slight peridontal inflammation. A 5-fold increase in the concentration of fusobacterial antigen resulted in increased stimulation of migration or inhibition of migration. Preincubation of the leukocytes with puromycin abolished both inhibition and stimulation of migration by candidal or fusobacterial antigen. The study confirms that it is important to study dose-related effects when applying the LMAT to test cell-mediated immunity. The study is in support of stimulation of migration being an immunologic reaction.
Abstract 20597: Phenotype of Culprit Plaque Calcification Differs between Elderly and Young Patients with ST-segment Elevation Myocardial Infarction -Morphological Analysis by Virtual Histology-Intravascular Ultrasound-
Authors: Kousei Ohshima, Shuntaro Ikeda, Hisaki Kadota, Kenichi Yamane, Naoki Izumi, Hiroshi Kawazoe, Kiyotaka Ohshima, Mareomi Hamada
Journal: Circulation (2010)

Objectives: It is well known calcium deposition of atherosclerotic plaque is associated with plaque vulnerability and pathogenesis of acute coronary syndrome. Recent studies have shown coronary cal...
New Rules Require Financial Disclosure
Authors: Stuart L. Nightingale
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 20470: Lower Mortality and Stent Thrombosis Rates Associated With Introduction of Potent P2Y12 Inhibitors in Patients With Acute Coronary Syndromes
Authors: Javaid Iqbal, Rebecca Rowe, Yao-Jun Zhang, Yasir Parviz, Allison C Morton, Ever Grech, Julian P Gunn, Robert F Storey
Journal: Circulation (2014)

Aims: We investigated the impact of new platelet P2Y12 inhibitors, prasugrel and ticagrelor, compared with clopidogrel, upon mortality and stent thrombosis (ST) in patients with acute coronary syndromes (ACS) in a large, single-centre, ‘all-comers’ population. Methods: Data were collected for 6742 consecutive patients attending the cardiac catheterization lab at Sheffield, UK (2009-2013) with ACS. Differences in outcomes among patients receiving different P2Y12 inhibitors were evaluated at 12 months by Kaplan-Meier curves and log-rank test in the overall and a propensity-matched population. Results: Of 6742 patients with ACS (36% STEMI, 64% NSTE-ACS), 67% (4525) received clopidogrel, 15% (1007) prasugrel and 18% (1210) ticagrelor, with aspirin for all. In the overall group, prasugrel (HR 0.78, 95% CI 0.59-1.02, p=0.07) and ticagrelor (HR 0.77, 95% CI 0.60-0.99, p=0.04) were associated with lower all-cause mortality compared with clopidogrel (Fig 1A). There was no difference in mortality between prasugrel- and ticagrelor-treated groups (HR 1.01, 95% CI 1.00-1.67, p=0.96). The incidence of definite/probable ST was 4.2% (1.5% definite, 2.7% probable) at 12 months. ST rates were nearly 2-fold higher in patients treated with either clopidogrel or prasugrel compared with ticagrelor (Fig 1B). In the STEMI subgroup, lower mortality and ST rates were observed with new P2Y12 inhibitors but no significant differences between prasugrel and ticagrelor (Fig 1C and 1D). The results for all ACS population or STEMI subgroup remained similar after adjustment for confounding variables or analysing propensity-matched cohorts. Conclusions: Both prasugrel and ticagrelor appear superior to clopidogrel for reduction in mortality in ACS in the ‘real world’. Ticagrelor was associated with the lowest mortality and ST rates in all ACS patients, whereas either prasugrel or ticagrelor appear suitable in STEMI patients without contraindications.
Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites
Authors: Sietske A. Riemersma, Ekaterina S. Jordanova, Roelandt F. J. Schop, Katja Philippo, Leendert H. J. Looijenga, Ed Schuuring, Philip M. Kluin
Journal: Blood (2000)
USE OF A "DOUBLE-BLIND" STUDY INVESTIGATING THE CLINICAL MERITS OF A NEW TRANQUILIZING AGENT
Authors: H KOTEEN
Journal: Annals of Internal Medicine (1957)

ExcerptPhysicians and all groups who participate in helping sick people are aware that emotional patterns influence sense of well being and physical health. The success of the witchcraft doctor and the numerous healing cults is in large measure dependent upon the fact that patients achieve a sense of security from discussing their problems with a responsible and sympathetic person, whether he be a recognized physician or simply someone assuming that role. An extensive effort has been made to find therapeutic agents which will relieve emotional tension without impairing intellectual function. The earlier hypnotics, including paraldehyde, chloral hydrate and the bromides,...
Epilepsy: A Comprehensive Textbook
Authors: Jerome Engel, Timothy A. Pedley, Jean Aicardi
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE EFFECT OF DISODIUM CROMOGLYCATE* IN PERENNIAL ALLERGIC RHINITIS
Authors: A. WARLAND, B. KAPSTAD
Journal: Allergy (1977)

The clinical effect of disodium cromoglycate was compared with placebo in patients with perennial allergic rhinitis. The results of a double-blind cross-over trial in 17 patients suggest that insufflation with 10 mg disodium cromoglycate four times a day has no better effect than placebo. No significant differences between the side effect of disodium cromoglycate and placebo were noted.
SURGERY IN THE PATIENT OVER SEVENTY
Authors: A J RYAN
Journal: Annals of Internal Medicine (1952)

Article1 June 1952SURGERY IN THE PATIENT OVER SEVENTYALLAN J. RYAN, M.D.ALLAN J. RYAN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-36-6-1437 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe problem facing the patient over 70 who suffers from a condition requiring surgical treatment so often is not (as the relatives think) whether he can stand the operation as whether he can survive without it. Men and women between the ages of 60 and 70 already make up such a large part of surgical practice that they are no longer considered to present a special problem. There is still considerable reluctance, however, on the part of the average physician as well as the layman to advise or accept surgery for those who have passed the traditional span of three-score-and-ten....Bibliography1. Welch CS: Surgery in the aged, New England J. Med. 238: 821-832, 1948. CrossrefMedlineGoogle Scholar2. Brooks B: Surgery in patients of advanced age, Ann. Surg. 105: 481, 1937. CrossrefMedlineGoogle Scholar3. ZiffrenZagerCullen SELLSC: Hazards of surgery beyond the age of eighty, Geriatrics 5: 252, 1950. MedlineGoogle Scholar4. Cutler CW: Urgent surgery in the aged, Ann. Surg. 126: 763, 1947. CrossrefGoogle Scholar5. Byrd BF: Cancer of the breast in advanced age groups, Surgery 27: 414-416, 1950. Google Scholar6. Cutler CW: Biliary tract emergencies in the aged, S. Clin. North America 29: 361-368, 1949. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Meriden, Connecticut*Received for publication November 5, 1951. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPRACTICAL CONSIDERATIONS IN THE MANAGEMENT OF THE GERIATRIC SURGICAL PATIENTLa Chirurgie et L’anesthesie chez les Vieillards 1 June 1952Volume 36, Issue 6Page: 1437-1443KeywordsSurgery Issue Published: 1 June 1952 PDF downloadLoading ...
Abstract 13374: Enhancing Myocardial Repair with CardioChimeras
Authors: Pearl J Quijada, Hazel T Salunga, Jonathan Cubillo, Jacqueline Emathinger, Mark A Sussman
Journal: Circulation (2014)

Transplantation of cardiac progenitor cells (CPCs) and mesenchymal stem cells (MSCs) after infarction support modest improvements in cardiac function, however there are currently no reports substantiating a single stem cell type supporting both direct and indirect mechanisms of repair. Therefore, we created a CardioChimera (CC), a progenitor cell formed by fusion between CPCs and MSCs, resulting in a unique progeny superior to either individual precursor. CardioChimeras are mono-nucleated, have unique growth kinetics and do not display increases in cell death relative to parental CPCs and MSCs. CCs have increased cellular size unrelated to cell cycle arrest and/or senescence based on mRNA analysis of p16 and p53. As proof of principle, CCs co-cultured with serum starved cardiomyocytes blunted myocyte cell death (2-fold) relative to parent cells and increased myocyte size not observed with co-culture of CPCs alone. CCs enhance myocyte growth similar to parent MSCs owing to an increased propensity to secret...
Abstract 20514: Adults With Hypoplastic Left Heart Syndrome: Outcomes in a New Cohort of Patients
Authors: William M Wilson, Candice Silversides, Anne Valente, Erwin Oechslin, S. Lucy Roche, Luke Burchill, Craig Broberg, Edward Hickey, Leeanne Grigg, Eliza Teo, Isabelle Von Der Muhll, Patrick Gibson, Jasmine Grewal, Paul Khairy, Matthias Greutmann, Kelsey Hickey, Yaso Emmanuel, Paul Clift, Rachel Wald
Journal: Circulation (2014)

Background: Surgical palliation of hypoplastic left heart syndrome (HLHS) has only been possible for the past few decades. Prior to this, without heart transplantation, HLHS was universally fatal in infancy. The oldest survivors of palliated HLHS are only now entering adulthood and limited data are available regarding their welfare. Methods: For this multi-center, cross-sectional, observational study, 6 adult congenital heart disease (ACHD) centers contributed data regarding all HLHS patients aged &gt;18 years followed at their institution. HLHS was defined as a dominant right ventricle (RV) and diminutive left ventricle with a combination of mitral valve disease (stenosis [MS] or atresia [MA]) and aortic valve disease (stenosis [AS] or atresia [AA]). Patients with single RV physiology without hypoplasia of left heart inlet and outlet structures were excluded. All available clinical data, including cardiac imaging, cardiac catheterization results and exercise tests were reviewed. Results: The study included 53 HLHS adults (65% male) with mean age 21.8±3.6 years. Underlying cardiac anatomy was AA&amp;MA (n=21, 41%), AS&amp;MS (n=19, 37%), AS&amp;MA (n=10, 20%), and AA&amp;MS (n=1, 2%). Stage 1 Norwood was completed at age 6.0±4.4 days, Glenn shunt at age 10.8±8.7 months and Fontan at age 3.3±2 years. Stage 1 cardiopulmonary bypass and circulatory arrest times were 94±46 and 59±2 minutes respectively. The mean duration of follow-up in an ACHD center was 3.4±2.5 years. After age 18 years, major adverse events had occurred in 15/53 patients (28%). These mutually exclusive events were: death (n=3, 6%), transplant (n=1, 2%), protein losing enteropathy (n=2, 4%), stroke (n=2, 4%), symptomatic ventricular tachycardia (n=1, 2%), heart failure requiring admission for intravenous therapy (n=3, 6%) and major cardiac surgery (n=3, 6% [aortic valve replacement n=1, tricuspid valve replacement n=2]). Conclusions: Young adults with a Fontan palliation for HLHS are at high risk of major adverse cardiac events. It is essential that close attention is paid to successful transition of this vulnerable population into adult care and that these patients remain under vigilant specialist follow-up through adult life.
A GCH1 haplotype confers sex‐specific susceptibility to pain crises and altered endothelial function in adults with sickle cell anemia
Authors: Inna Belfer, Victoria Youngblood, Deepika S. Darbari, Zhengyuan Wang, Lena Diaw, Lita Freeman, Krupa Desai, Michael Dizon, Darlene Allen, Colin Cunnington, Keith M. Channon, Jacqueline Milton, Stephen W. Hartley, Vikki Nolan, Gregory J. Kato, Martin H. Steinberg, David Goldman, James G. Taylor
Journal: American Journal of Hematology (2013)

GTP cyclohydrolase (GCH1) is rate limiting for tetrahydrobiopterin (BH4) synthesis, where BH4 is a cofactor for nitric oxide (NO) synthases and aromatic hydroxylases. GCH1 polymorphisms are implicated in the pathophysiology of pain, but have not been investigated in African populations. We examined GCH1 and pain in sickle cell anemia where GCH1 rs8007267 was a risk factor for pain crises in discovery ( n = 228; odds ratio [OR] 2.26; P = 0.009) and replication ( n = 513; OR 2.23; P = 0.004) cohorts. In vitro , cells from sickle cell anemia subjects homozygous for the risk allele produced higher BH4. In vivo physiological studies of traits likely to be modulated by GCH1 showed rs8007267 is associated with altered endothelial dependent blood flow in females with SCA (8.42% of variation; P = 0.002). The GCH1 pain association is attributable to an African haplotype with where its sickle cell anemia pain association is limited to females (OR 2.69; 95% CI 1.21–5.94; P = 0.01) and has the opposite directional association described in Europeans independent of global admixture. The presence of a GCH1 haplotype with high BH4 in populations of African ancestry could explain the association of rs8007267 with sickle cell anemia pain crises. The vascular effects of GCH1 and BH4 may also have broader implications for cardiovascular disease in populations of African ancestry. Am. J. Hematol. 89:187–193, 2014. © 2013 Wiley Periodicals, Inc.
BACTERIOLOGICAL DIAGNOSIS OF TUBERCULOSIS
Authors: Nicolas Veziris
Journal: BMJ (1938)

Today, microscopic examination and culture are still essential for active tuberculosis diagnosis and therapeutic decisions. Nucleic acid amplification and line probe assays speed up identification and susceptibility testing of mycobacteria in AFB smear positive specimens or in culture. They are also efficient for comparison of M. tuberculosis strains with each other (genotyping). On the other hand, today, molecular tests are not relevant for the diagnosis in smear negative specimens and even more for diagnosis of culture-negative tuberculosis.
Abstract 15993: Does Optical Coherence Tomography Guided Percutaneous Coronary Intervention Reduce Resource Utilization?
Authors: Ricardo Cigarroa, Eugene Pomerantsev, Hang Lee, Ik-kyuk Jang
Journal: Circulation (2014)

Background: Optical coherence tomography (OCT) was recently introduced to optimize percutaneous coronary intervention (PCI). Pre-PCI OCT evaluation may help develop optimal strategy and potentially reduce resource utilization.

Aims: To test the hypothesis that OCT-guided PCI, compared to angio-guided PCI, would reduce resource utilization.

Methods and Results: A total of 429 PCI cases were selected from the cath lab database: 143 OCT-guided and 286 angio-guided cases. They were matched on propensity score derived from a logistic model determined by clinical and angiographic factors. Resources studied included number of stents, number of balloons, procedure time, contrast volume, and fluoroscopy time. OCT-guided cases had a significant shorter fluoroscopy time compared to angio-guided cases (16.5 vs. 20.5 min, p=0.006), but no significant difference was observed in balloon usage, stent usage, procedure time, or contrast volume.

Conclusions: This study failed to demonstrate that OCT-guided PCI reduces resource utilization compared to angio-guided PCI. Investigation of whether OCT-guided PCI improves clinical outcome requires large scale prospective studies.

   ![][1]  [1]: /embed/graphic-1.gif
Baseline Cystatin C is Associated with Short-Term Adverse Events in Acute Heart Failure but Does Not Predict Treatment Effects with Nesiritide Therapy
Authors: W. H. Wilson Tang, G. Michael Felker, Adrian F. Hernandez, Amy P. Hsu, Stephen S. Gottlieb, Adriaan A. Voors, Javed Butler, Marco Metra, Stefan D. Anker, Richard W. Troughton, John J. McMurray, Paul W. Armstrong, Barry M. Massie, Robert M. Califf, Christopher M. O'Connor, Randall C. Starling
Journal: Circulation (2011)
SAT0179 Serum rituximab levels and efficiency of B-cell depletion: Differences between patients with systemic lupus erythematosus and rheumatoid arthritis
Authors: V. Reddy, S. Croca, D. Gerona, I.D.L.T. Ortega, D. Isenberg, M. Leandro, G. Cambridge
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Variability in rituximab-induced B cell depletion (BCD) occurs in a significant number of patients with Systemic Lupus Erythematosus (SLE) and to a lesser extent in patients with Rheumatoid Arthritis (RA). A failure to adequately deplete (CD19+ B cells &lt;5/μl) probably underlies poor clinical response in many patients with SLE. In this prospective study, we investigated whether the levels of rituximab influence the degree of peripheral BCD. <h3>Objectives</h3> To determine the serum levels of rituximab at 1 and 3 months post-rituximab in SLE and RA in conjunction with the measurement of absolute number of peripheral CD19+ B cells. <h3>Methods</h3> A total of 16 patients with SLE were included and 23 with RA. All patients were treated with rituximab (2 x 1g doses given 2 week apart). Rituximab levels at 1 and 3 months post treatment were measured with a capture ELISA using sera diluted at a concentration of 1/40,000. CD19 counts were determined by flow cytometry. Adequate depletion was defined as CD19+ count below 5cells/ml. Data were compared using the Mann Whitney U test for non-parametric data and the Spearman Rank for correlation. <h3>Results</h3> At 1 month, 6 of 15 (40%) patients with SLE and 6 of 23 (26%) patients with RA had CD19 counts &gt;5 cells/ml. The median CD19 count in these patients was 0.02cells/μl and 0.008cells/μl for SLE and RA, respectively. The levels of rituximab were significantly lower in SLE when compared with RA, at both 1 and 3 months after rituximab treatment. The median rituximab level at 1 month for SLE was 43.07μg/ml (range 0-777) and for RA, 391.9μg/ml (range 1.3-2500) (p=0.0008). The median rituximab level at 3 months was 0μg/ml (range 0-54) for SLE and 2.6μg/ml (range 0-1153) for RA (p=0.008). Amongst patients who had depleted well, rituximab levels were significantly lower in patients with SLE when compared with patients who have RA at 1 month (p=0.003) and also at 3 months (p=0.008). No such difference was found in patients who did not deplete well. Six patients with SLE had lupus nephritis (LN) and the presence of LN did not influence the levels of rituximab or the degree of BCD, in this small group of patients. The levels of rituximab correlated inversely with the absolute numbers of CD19+ B cells in patients with RA at 1 month (r<sup>2</sup>=0.69) and in patients with SLE at 3 months (r<sup>2</sup>=0.51). <h3>Conclusions</h3> Our data indicated that patients with SLE had markedly (&gt;9 fold at 1 month) lower serum levels than RA patients at both 1 and 3 months. However, a higher proportion of patients with SLE depleted less well with significantly higher residual CD19+ B cells due to factors involved in the clearance of rituximab such as impaired recycling through FcRn, internalisation and destruction by target B cells. <h3>Disclosure of Interest</h3> None Declared
Abstract 12781: Statin Use and Venous Thromboembolism Recurrence: A Combined Nationwide Cohort and Nested Case-control Study
Authors: Morten Schmidt, Suzanne C. Cannegieter, Sigrun A Johannesdottir, Olaf M Dekkers, Erzsebet Horvath-Puho, Henrik T Sorensen
Journal: Circulation (2013)

Background: Statins’ effect on venous thromboembolism (VTE) recurrence remains unclear. We examined this association. Methods: We conducted a nationwide population-based cohort study and a suppleme...
End-stage liver disease in persons with hemophilia and transfusion-associated infections.
Authors: James J. Goedert, M. Elaine Eyster, Michael M. Lederman, Titica Mandalaki, Philippe de Moerloose, Gilbert C. White, Anne L. Angiolillo, Naomi L. C. Luban, Kenneth E. Sherman, Marilyn Manco-Johnson, Liliana Preiss, Cindy Leissinger, Craig M. Kessler, Alan R. Cohen, Donna DiMichele, Margaret W. Hilgartner, Louis M. Aledort, Barbara L. Kroner, Philip S. Rosenberg, Angelos Hatzakis
Journal: Blood (2002)